A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)

NCT06698042 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer
Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: Pembrolizumab (+) Berahyaluronidase alfa
BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC